ActoBiotics®

Intrexon Corporation offers a wide range of technologies which includes ActoBiotics®. Feature: it is a new class of orally delivered biopharmaceuticals. Through our proprietary platform, food-grade microbes (Lactococcus lactis) are engineered to generate biologically contained ActoBiotics® therapeutics for in situ expression and secretion of novel proteins and peptides including cytokines, enzymes, hormones, and monoclonal antibodies within the body. The ActoBiotics® platform offers the unique ability to deliver biological effectors selectively to the oral and gastrointestinal tract enabling treatment opportunities not achievable through customary mechanisms like injectable medicines and permitting ease of administration for patients. With intervention focused at the site of pathology, this groundbreaking class of orally available biopharmaceuticals has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases. Contact us for more information.